Pharmacological Pupil Testing: Localising the Lesion With Drops

Two nerves, one pupil

The size of the pupil at any moment is a tug-of-war between two autonomic muscles. The iris carries two opposing muscles, each on its own nerve. The sphincter pupillae constricts the pupil and is driven by the parasympathetic system: fibres leave the midbrain with the third cranial nerve (CN III), synapse in the ciliary ganglion, and reach the sphincter as short ciliary nerves — the muscarinic (M3) receptor is the effector, so acetylcholine constricts. The dilator pupillae widens the pupil and is driven by the sympathetic system through a long, three-neuron chain: from the hypothalamus down the brainstem and cord to the C8–T1 level (first-order), out to the superior cervical ganglion in the neck (second-order), then up along the carotid artery to the iris (third-order), releasing noradrenaline onto alpha-1 receptors. Constriction is a short, tidy parasympathetic loop; dilation is a long sympathetic relay that hugs the carotid and the lung apex. This same wiring is laid out in full in the Autonomic Nervous System chapter — the pupil is simply its most examinable output.

The principle: denervation supersensitivity

Cut a muscle's nerve and the muscle does not simply fall silent — it grows hungry. When a muscle loses its nerve supply, it stops receiving its usual neurotransmitter. In response, over days, it up-regulates receptors across its surface, becoming far more sensitive to whatever agonist does eventually reach it. This is denervation supersensitivity, and it is the engine of the whole pharmacological pupil work-up. A denervated iris muscle will over-respond to a weak dose of an agonist that a normally innervated muscle would barely notice. So the test design is always the same: apply a low or ordinary concentration of an agonist, and watch which pupil moves. If the denervated pupil moves and the normal one doesn't, you have both confirmed the lesion and, because the receptors that up-regulate depend on which neuron died, learned something about where it is. The principle itself belongs to the Principles of Pharmacology chapter, where receptor up-regulation is taught as the mirror image of the tolerance that down-regulation produces.

Horner's syndrome: confirming it with a drop

Horner's syndrome is the clinical picture of a broken sympathetic chain to the eye: miosis (a small pupil, because the dilator has lost its drive), partial ptosis (the sympathetically-innervated Müller's muscle helps hold the lid up), and — if the lesion is proximal enough — anhidrosis (loss of sweating over the affected side of the face). The anisocoria is greater in dim light, because that is when the healthy eye's dilator should be pulling its pupil wide and the Horner's pupil cannot follow. The modern confirmatory test is topical apraclonidine, an alpha-agonist. Apraclonidine is a weak direct alpha-1 agonist (and a stronger alpha-2 agonist). In a normal iris its feeble alpha-1 action does almost nothing. But the Horner's dilator, denervated and supersensitive, has up-regulated its alpha-1 receptors — so that same weak drop makes it contract and the small pupil dilates. The anisocoria reverses: the previously smaller Horner's pupil becomes the larger, and the ptotic lid often lifts. A reversal of anisocoria is a positive test.

The older cocaine test works on the opposite logic — blockade, not supersensitivity. Before apraclonidine, the classic confirmatory agent was topical cocaine. Cocaine blocks the reuptake of noradrenaline at the dilator's nerve ending, so noradrenaline accumulates and a normally innervated pupil dilates. But this only works if noradrenaline is actually being released — and in Horner's the sympathetic supply is cut, so there is little or no noradrenaline to accumulate. The Horner's pupil therefore fails to dilate, while the normal pupil widens: the anisocoria increases. Cocaine is being replaced by apraclonidine in most clinics because it is easier to obtain, store and interpret — but the two tests read out in mirror-image ways, and confusing them is a classic exam trap. Cocaine: the abnormal pupil stays small (fails to dilate). Apraclonidine: the abnormal pupil flips to become the larger one.

Once Horner's is confirmed, a second drop asks how far down the chain the break is. Confirming Horner's is only half the job — the urgent question is where the lesion sits, because a post-ganglionic lesion (along the carotid or in the cavernous sinus) has a very different differential from a pre-ganglionic or central one (an apical lung tumour, a cord lesion). The traditional localiser is topical hydroxyamphetamine, a drug that acts indirectly: it makes the third-order (post-ganglionic) neuron release its stored noradrenaline. That only works if the post-ganglionic neuron is intact. So if the lesion is pre-ganglionic (first- or second-order), the terminal neuron is alive and stocked with noradrenaline — hydroxyamphetamine releases it and the Horner's pupil dilates. If the lesion is post-ganglionic (third-order), the terminal neuron itself has degenerated, its noradrenaline stores are empty, and there is nothing to release — the pupil fails to dilate. Failure to dilate therefore points to a post-ganglionic lesion. It is an elegant use of an indirect sympathomimetic to interrogate the last neuron in the chain. This pre- versus post-ganglionic split, and its differential, is developed further in the Neuro-ophthalmology chapter.

Adie's tonic pupil: the weak-pilocarpine test

Swing to the parasympathetic side. Adie's tonic pupil is caused by damage to the post-ganglionic parasympathetic supply — the ciliary ganglion or the short ciliary nerves. The pupil is large and reacts poorly, sluggishly or not at all, to light; but on attempted near focus it constricts slowly and then re-dilates slowly — the classic light-near dissociation, with a slow "tonic" quality to any movement it does make. Left denervated, the sphincter up-regulates its muscarinic receptors and becomes supersensitive to acetylcholine. This is exploited with dilute (low-concentration) pilocarpine — pilocarpine is a direct muscarinic agonist, and here it is deliberately used well below its ordinary strength. A drop of dilute pilocarpine constricts the supersensitive Adie's pupil noticeably, while barely touching the normal pupil, whose innervated sphincter is not sensitised. A large, poorly reactive pupil that constricts briskly to weak pilocarpine is Adie's. Reassuringly, when paired with absent deep tendon reflexes (Holmes–Adie syndrome), it is usually a benign, chronic condition rather than a dangerous one.

The fixed dilated pupil: nerve palsy or a drop in the eye?

A blown pupil frightens everyone — but not every blown pupil is a brain in trouble. A unilateral fixed, dilated pupil raises the spectre of a third-nerve palsy — classically from a posterior communicating artery aneurysm compressing CN III, an emergency. But a far more common and entirely benign cause is pharmacological (atropinic) mydriasis: an anti-muscarinic agent has reached the eye and paralysed the sphincter. The culprit may be a scopolamine (hyoscine) motion-sickness patch rubbed into the eye by a stray finger, a nebulised anticholinergic like ipratropium leaking under a loose mask, a handled plant alkaloid, or a deliberately instilled mydriatic. The test that separates them is full-strength pilocarpine. In a third-nerve palsy the sphincter muscle and its receptors are healthy — the problem is upstream, a lack of neural drive — so a strong muscarinic agonist reaches live receptors and the pupil constricts. In pharmacological mydriasis the muscarinic receptors are already occupied and blocked by the offending anti-muscarinic, so even full-strength pilocarpine cannot dock and the pupil does not constrict. A dilated pupil that fails to constrict to strong pilocarpine is pharmacologically blocked — the "someone got a mydriatic in the eye" result — and should stop you before you send a well patient for an emergency angiogram. The mydriatic agents themselves are covered in the Mydriatics chapter.

The non-pharmacological companion: the swinging-light test

Not every pupil problem is a drug problem, and the most important bedside test needs no bottle at all. The relative afferent pupillary defect (RAPD), elicited by the swinging-light test, checks the input side of the reflex — the optic nerve and retina — rather than the motor output the drops interrogate. You swing a bright light rhythmically from one eye to the other. Normally each eye, when lit, drives brisk constriction of both pupils. But if one optic nerve is diseased (an optic neuritis, a compressive lesion, severe glaucoma), the brain "sees" less light from that eye: when the light swings to the affected side, both pupils paradoxically dilate, because the reduced afferent signal is weaker than the consensual drive they were just receiving from the good eye. A positive RAPD localises the problem to the afferent pathway — the pupil size may be normal — whereas the pharmacological tests interrogate the efferent, autonomic supply. Together they let you dissect an unequal or unreactive pupil into its input and output halves at the bedside.